Trevi Therapeutics
TRVI
110 hedge funds and large institutions have $330M invested in Trevi Therapeutics in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 24 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
96% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 24
70% more capital invested
Capital invested by funds: $194M → $330M (+$135M)
18% more funds holding
Funds holding: 93 → 110 (+17)
8.89% more ownership
Funds ownership: 80.07% → 88.95% (+8.9%)
13% less call options, than puts
Call options by funds: $927K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.3M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$10.5M |
| 3 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$9.3M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$8.34M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$6.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.8M |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.63M |
| 4 |
ABG
Ally Bridge Group
New York
|
-$1.73M |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
-$1.19M |
TRVI Hedge Fund Activity: Q4 2024 in Review
110 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q4 2024, worth a combined $330M — up 70% from $194M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new TRVI positions and 7 closed out — a net gain of 19 holders — while 47 added to existing stakes and 24 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $13.3M. The largest seller was VR Adviser, cutting an estimated $6.9M.
- 110 institutional investors held Trevi Therapeutics (TRVI) as of Q4 2024, up from 93 in Q3 2024.
- Funds reported $330M of Trevi Therapeutics stock for Q4 2024, up 70% quarter-over-quarter.
- 26 funds opened new Trevi Therapeutics positions in Q4 2024 and 7 closed out, a net change of +19 holders.
- The largest Trevi Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $13.3M added.
- The largest Trevi Therapeutics seller in Q4 2024 was VR Adviser, an estimated $6.9M sold.
Based on aggregated 13F filings for Q4 2024.